PortalPublikationenMonitoring the systemic human memory B cell compartment of m...

Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies

Standard

Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. / Gilbert, Amy E; Karagiannis, Panagiotis; Dodev, Tihomir; Koers, Alexander; Lacy, Katie; Josephs, Debra H; Takhar, Pooja; Geh, Jenny L C; Healy, Ciaran; Harries, Mark; Acland, Katharine M; Rudman, Sarah M; Beavil, Rebecca L; Blower, Philip J; Beavil, Andrew J; Gould, Hannah J; Spicer, James; Nestle, Frank O; Karagiannis, Sophia N.

in: PLOS ONE, Jahrgang 6, Nr. 4, 29.04.2011, S. e19330.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gilbert, AE, Karagiannis, P, Dodev, T, Koers, A, Lacy, K, Josephs, DH, Takhar, P, Geh, JLC, Healy, C, Harries, M, Acland, KM, Rudman, SM, Beavil, RL, Blower, PJ, Beavil, AJ, Gould, HJ, Spicer, J, Nestle, FO & Karagiannis, SN 2011, 'Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies', PLOS ONE, Jg. 6, Nr. 4, S. e19330. https://doi.org/10.1371/journal.pone.0019330

APA

Gilbert, A. E., Karagiannis, P., Dodev, T., Koers, A., Lacy, K., Josephs, D. H., Takhar, P., Geh, J. L. C., Healy, C., Harries, M., Acland, K. M., Rudman, S. M., Beavil, R. L., Blower, P. J., Beavil, A. J., Gould, H. J., Spicer, J., Nestle, F. O., & Karagiannis, S. N. (2011). Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLOS ONE, 6(4), e19330. https://doi.org/10.1371/journal.pone.0019330

Vancouver

Gilbert AE, Karagiannis P, Dodev T, Koers A, Lacy K, Josephs DH et al. Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLOS ONE. 2011 Apr 29;6(4):e19330. https://doi.org/10.1371/journal.pone.0019330

Bibtex

@article{4f445c748f4440509f38ea73cd0d356e,
title = "Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies",
abstract = "Melanoma, a potentially lethal skin cancer, is widely thought to be immunogenic in nature. While there has been much focus on T cell-mediated immune responses, limited knowledge exists on the role of mature B cells. We describe an approach, including a cell-based ELISA, to evaluate mature IgG antibody responses to melanoma from human peripheral blood B cells. We observed a significant increase in antibody responses from melanoma patients (n = 10) to primary and metastatic melanoma cells compared to healthy volunteers (n = 10) (P<0.0001). Interestingly, we detected a significant reduction in antibody responses to melanoma with advancing disease stage in our patient cohort (n = 21) (P<0.0001). Overall, 28% of melanoma patient-derived B cell cultures (n = 1,800) compared to 2% of cultures from healthy controls (n = 600) produced antibodies that recognized melanoma cells. Lastly, a patient-derived melanoma-specific monoclonal antibody was selected for further study. This antibody effectively killed melanoma cells in vitro via antibody-mediated cellular cytotoxicity. These data demonstrate the presence of a mature systemic B cell response in melanoma patients, which is reduced with disease progression, adding to previous reports of tumor-reactive antibodies in patient sera, and suggesting the merit of future work to elucidate the clinical relevance of activating humoral immune responses to cancer.",
keywords = "Antibodies, Monoclonal/chemistry, Antibodies, Neoplasm/chemistry, B-Lymphocytes/immunology, Case-Control Studies, Cell Line, Cell Line, Tumor, Cohort Studies, Disease Progression, Enzyme-Linked Immunosorbent Assay/methods, Fibroblasts/metabolism, Humans, Immune System, Immunoglobulin G/blood, Immunohistochemistry/methods, Melanoma/blood, Time Factors",
author = "Gilbert, {Amy E} and Panagiotis Karagiannis and Tihomir Dodev and Alexander Koers and Katie Lacy and Josephs, {Debra H} and Pooja Takhar and Geh, {Jenny L C} and Ciaran Healy and Mark Harries and Acland, {Katharine M} and Rudman, {Sarah M} and Beavil, {Rebecca L} and Blower, {Philip J} and Beavil, {Andrew J} and Gould, {Hannah J} and James Spicer and Nestle, {Frank O} and Karagiannis, {Sophia N}",
year = "2011",
month = apr,
day = "29",
doi = "10.1371/journal.pone.0019330",
language = "English",
volume = "6",
pages = "e19330",
journal = "PLOS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

RIS

TY - JOUR

T1 - Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies

AU - Gilbert, Amy E

AU - Karagiannis, Panagiotis

AU - Dodev, Tihomir

AU - Koers, Alexander

AU - Lacy, Katie

AU - Josephs, Debra H

AU - Takhar, Pooja

AU - Geh, Jenny L C

AU - Healy, Ciaran

AU - Harries, Mark

AU - Acland, Katharine M

AU - Rudman, Sarah M

AU - Beavil, Rebecca L

AU - Blower, Philip J

AU - Beavil, Andrew J

AU - Gould, Hannah J

AU - Spicer, James

AU - Nestle, Frank O

AU - Karagiannis, Sophia N

PY - 2011/4/29

Y1 - 2011/4/29

N2 - Melanoma, a potentially lethal skin cancer, is widely thought to be immunogenic in nature. While there has been much focus on T cell-mediated immune responses, limited knowledge exists on the role of mature B cells. We describe an approach, including a cell-based ELISA, to evaluate mature IgG antibody responses to melanoma from human peripheral blood B cells. We observed a significant increase in antibody responses from melanoma patients (n = 10) to primary and metastatic melanoma cells compared to healthy volunteers (n = 10) (P<0.0001). Interestingly, we detected a significant reduction in antibody responses to melanoma with advancing disease stage in our patient cohort (n = 21) (P<0.0001). Overall, 28% of melanoma patient-derived B cell cultures (n = 1,800) compared to 2% of cultures from healthy controls (n = 600) produced antibodies that recognized melanoma cells. Lastly, a patient-derived melanoma-specific monoclonal antibody was selected for further study. This antibody effectively killed melanoma cells in vitro via antibody-mediated cellular cytotoxicity. These data demonstrate the presence of a mature systemic B cell response in melanoma patients, which is reduced with disease progression, adding to previous reports of tumor-reactive antibodies in patient sera, and suggesting the merit of future work to elucidate the clinical relevance of activating humoral immune responses to cancer.

AB - Melanoma, a potentially lethal skin cancer, is widely thought to be immunogenic in nature. While there has been much focus on T cell-mediated immune responses, limited knowledge exists on the role of mature B cells. We describe an approach, including a cell-based ELISA, to evaluate mature IgG antibody responses to melanoma from human peripheral blood B cells. We observed a significant increase in antibody responses from melanoma patients (n = 10) to primary and metastatic melanoma cells compared to healthy volunteers (n = 10) (P<0.0001). Interestingly, we detected a significant reduction in antibody responses to melanoma with advancing disease stage in our patient cohort (n = 21) (P<0.0001). Overall, 28% of melanoma patient-derived B cell cultures (n = 1,800) compared to 2% of cultures from healthy controls (n = 600) produced antibodies that recognized melanoma cells. Lastly, a patient-derived melanoma-specific monoclonal antibody was selected for further study. This antibody effectively killed melanoma cells in vitro via antibody-mediated cellular cytotoxicity. These data demonstrate the presence of a mature systemic B cell response in melanoma patients, which is reduced with disease progression, adding to previous reports of tumor-reactive antibodies in patient sera, and suggesting the merit of future work to elucidate the clinical relevance of activating humoral immune responses to cancer.

KW - Antibodies, Monoclonal/chemistry

KW - Antibodies, Neoplasm/chemistry

KW - B-Lymphocytes/immunology

KW - Case-Control Studies

KW - Cell Line

KW - Cell Line, Tumor

KW - Cohort Studies

KW - Disease Progression

KW - Enzyme-Linked Immunosorbent Assay/methods

KW - Fibroblasts/metabolism

KW - Humans

KW - Immune System

KW - Immunoglobulin G/blood

KW - Immunohistochemistry/methods

KW - Melanoma/blood

KW - Time Factors

U2 - 10.1371/journal.pone.0019330

DO - 10.1371/journal.pone.0019330

M3 - SCORING: Journal article

C2 - 21559411

VL - 6

SP - e19330

JO - PLOS ONE

JF - PLOS ONE

SN - 1932-6203

IS - 4

ER -